粘膜多糖症IVA治疗的最新进展
Andrés Felipe Leal1,2,3, Harry Pachajoa4,5,6
1Centro de Investigaciones en Anomalías Congénitas y Enfermedades Raras, Universidad Icesi, Cali, 760031, Colombia. lealb.af@javeriana.edu.co.
Orphanet journal of rare diseases
|October 15, 2025
概括
粘多糖症IVA (MPS IVA) 是一种罕见的遗传疾病,影响骨系统. 基因疗法和新药策略的近期进展表明,改善治疗方法比目前的酶替代疗法更有前途.
科学领域:
- 生物化学 生物化学
- 遗传学 是一个遗传学.
- 医学研究 医学研究
背景情况:
- 粘多糖症IVA (MPS IVA),或Morquio A综合征,是一种罕见的遗传溶酶体储存障碍.
- 它源于GALNS基因的突变,导致N-乙甲胺-6-硫酶 (GALNS) 缺乏.
- 这种缺陷会导致酸盐和酸-6-硫酸盐的积累,主要影响骨系统,导致渐进性发育不良和多器官干扰.
研究的目的:
- 审查最近的治疗进展,用于粘多糖症 IVA.
- 讨论超越酶替代疗法 (ERT) 的新策略.
- 探索新的治疗目标和方向,以改善患者的治疗结果.
主要方法:
- 对MPS IVA治疗方法的临床前和临床研究的审查.
- 对酶替代疗法 (ERT) 局限性的分析.
- 评估新兴疗法,包括基因疗法 (GT),药理伴侣,反感性疗法和细胞外囊泡.
- 探索新的治疗点,例如线粒体功能障碍.
主要成果:
- 目前的ERT (elosulfase alfa) 由于穿透软骨的不足,对骨病理的疗效有限.
- 使用AAV,LV和CRISPR/Cas9平台的基因治疗 (GT) 显示出显著的临床前进展.
- 药理学伴奏剂 (ezetimibe,pranlukast,bromocriptine) 和反感性疗法显示出潜在的疗法.
- 冠状细胞中的线粒体功能障碍被确定为MPS IVA病理学的潜在贡献因素.
结论:
- 新兴的疗法,如基因疗法和基于反感的方法,为MPS IVA的ERT提供了有前途的替代方案.
- 提高酶稳定性和向性,以及探索线粒体功能等新途径,对于推进MPS IVA治疗至关重要.
- 一个多方面的治疗策略可能是必要的,以有效地管理MPS IVA和改善患者的结果.
相关概念视频
Cystic Fibrosis: Management
474
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
474
iPS Cell Differentiation
3.0K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
3.0K
Inflammatory Bowel Disease IV: Pharmacological Management
517
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
517
Drugs for Treatment of Ulcerative Colitis in IBD
456
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
456
Drugs for Treatment of Diarrhea-Predominant IBS
631
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
631
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
488
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
488


